0812 GMT - Fresenius Medical Care's revenue estimates have been lowered by Jefferies due to constrained U.S. volume growth compared to prepandemic levels and a diverging growth outlook from U.S. rival DaVita, its analysts write. The German dialysis provider guides for 0.5% U.S. volume growth in 2025 and expects volumes to recover by 2% in 2026. On the contrary, DaVita guides for flat volume growth at the midpoint of its guidance in 2025 and refrained from long-term comments, hinting at a potentially slower growth across the market. Consequently, Jefferies lowers its 2025-29 revenue estimate but increases its adjusted EBIT target on the company's higher margins and raised savings ambitions. Jefferies analysts look for more updates on its strategy and future growth prospects at its June CMD, they add. Shares fall 0.9% to 45.07 euros.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 21, 2025 04:19 ET (08:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.